See Entire Prescribing Facts OPDIVO® (nivolumab) is indicated with the treatment of Grownup patients with classical Hodgkin lymphoma (cHL) that has relapsed or progressed following autologous hematopoietic stem mobile transplantation (HSCT) and brentuximab vedotin or right after three or more lines of systemic therapy that features autologous HSCT